Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST
June 23rd 2021Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.
Read More
First Oral Medication for Blood Thinning in Children Granted FDA Approval
June 22nd 2021The FDA also approved dabigatran etexilate oral pellets for the prevention of recurrent clots in patients aged 3 months to less than 12 years of age who have completed treatment for their first venous thromboembolism.
Read More
Trial Shows Combination Therapy Improves Survival for Certain Patients With COVID-19
June 22nd 2021Previous trials in non-hospitalized patients with COVID-19 suggested casirivimab and imdevimab reduced viral levels, shortened the time to resolution of symptoms and significantly reduced the risk of hospitalization or death.
Read More
BET Inhibitors May Be Effective In Preventing Certain Types of Prostate Cancer Drug Resistance
June 21st 2021According to the study, lineage plasticity—the shift in castration-resistant prostate cancers from resembling glandular cells to neuroendocrine cells—may potentially be overcome through the use of bromodomain and extra-terminal (BET) protein inhibitors.
Read More
Study Finds No Benefit to Adding Checkpoint Inhibitors to Anti-HER2 Breast Cancer Therapy
June 21st 2021The trial, in phase 3, is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody, atezolimumab, in patients with high-risk, HER2-positive early breast cancer.
Read More
Pharmacist Medication Insights: Tepotinib for Non-Small Cell Lung Cancer
June 21st 2021Earlier this year, the FDA granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc) for the treatment of adults with metastatic non-small cell lung cancer who are harboring MET exon 14 skipping alterations.
Watch
Jordan Tishler, MD, president of the Association of Cannabis Specialists and faculty at Harvard Medical School, discusses the importance of unbiased, knowledgeable providers being present at the site of sale of cannabis in order to provide accurate information on the appropriate use of medical cannabis for certain medical conditions.
Watch